177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma
Interventions: DRUG: Lutetium Lu 177 Dotatate
Sponsor: OHSU Knight Cancer Institute
Collaborators: Novartis|Oregon Health and Science University